9amHealth Raises $26M Series B as Chronic Care Economics Shift
9amHealth raised $26M in Series B funding led by Define Ventures to expand virtual cardiometabolic care beyond diabetes and obesity.
Healthcare spent years building a system where patients with chronic disease bounce between specialists, pharmacies, insurers, disconnected apps, and enough login credentials to qualify for a cybersecurity incident. Employers absorbed the costs while patients absorbed the frustration, and pharmaceutical spending kept climbing like a teenager with access to a parent’s credit card. Investors are now backing companies trying to compress that chaos into a single operational layer.
9amHealth, the San Diego-based virtual specialty care platform focused on cardiometabolic conditions, raised $26M in Series B funding led by Define Ventures, with participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures. The financing brings disclosed funding for 9amHealth to roughly $51M. The company was founded in 2021 by Frank Westermann, Anton Kittelberger, Paul Geevarghese, and Bernhard Schandl. Frank Westermann and Anton Kittelberger previously helped build mySugr, the diabetes management platform acquired by Roche in 2017, which matters because digital health investors stopped paying premiums for “engagement apps” years ago. Operators with actual healthcare execution experience still command attention.
The bigger signal behind the 9amHealth financing is not telemedicine because telemedicine already happened. The signal is that employers and investors increasingly view chronic disease management as infrastructure rather than benefits theater.
What Happened
9amHealth raised a $26M Series B round to expand its virtual specialty care platform beyond diabetes and obesity into broader chronic-condition management. Define Ventures led the financing, with participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures. The company operates a virtual care model focused on cardiometabolic conditions including diabetes, hypertension, obesity, and high cholesterol, combining clinicians, medication management, diagnostics, coaching, and remote monitoring inside a unified care experience.
That operational detail matters more than the funding headline itself because digital health produced an entire generation of companies that treated healthcare like a UI problem. Investors eventually learned that lesson the expensive way after startups layered prettier interfaces on top of broken systems without solving outcomes or reimbursement economics. 9amHealth is positioning itself differently by building around continuity of care and measurable economic outcomes rather than pure engagement metrics.
According to company-reported data, 9amHealth claims up to 4x ROI for employers and up to $284 in monthly gross savings per member. The company also reported a 2.1 A1c reduction in patients with elevated baseline levels, 14.5% body weight reduction, and medication adherence above 95%. Healthcare executives read those numbers differently than consumers do because consumers hear “better care,” while CFOs hear “maybe this stops the bleeding.”
Why This Matters
The rise of GLP-1 drugs fundamentally changed the economics of chronic care. Ozempic, Wegovy, Mounjaro, and related therapies created one of the largest pharmaceutical demand waves in modern healthcare, forcing employers to confront exploding pharmacy costs tied to obesity and diabetes treatment. Health plans started recalculating long-term risk exposure while investors realized cardiometabolic care had become one of the largest financial pressure points in employer-sponsored healthcare.
That created an opening for companies like 9amHealth because the real business opportunity is not merely prescribing GLP-1 medications. Plenty of startups can write prescriptions, but the difficult part is managing patient adherence, diagnostics, behavioral support, insurance coordination, specialist access, and long-term outcomes at scale without operational collapse. That distinction separates healthcare infrastructure companies from what many investors privately call “GLP-1 tourism startups,” where one category builds defensible systems while the other survives on paid-search ads and fragile customer acquisition economics.
9amHealth appears to understand the difference. The company’s integrated care model aligns with how employers increasingly evaluate healthcare vendors because point solutions are losing favor. Buyers want consolidated platforms capable of addressing multiple chronic conditions while reducing fragmented spending, and procurement teams got tired of managing endless vendors all promising to “transform care journeys” while employees still could not refill prescriptions without sitting on hold for 40 minutes.
Market Context
The cardiometabolic care market is becoming one of the most crowded and strategically important sectors in digital health. Companies including Omada Health, Virta Health, Teladoc Health, Ro, Found, and Noom all compete across different layers of obesity, diabetes, metabolic health, and chronic-condition management. Large incumbents are also moving aggressively into the category because the financial incentives became impossible to ignore.
Cardiometabolic disease drives a massive percentage of employer healthcare spending in the United States. Obesity alone affects more than 40% of U.S. adults, while diabetes affects more than 11% of the population. Those conditions create downstream costs touching cardiovascular disease, kidney disease, musculoskeletal conditions, and pharmacy spending, which means employers no longer view chronic-condition management as optional wellness programming. The category increasingly resembles enterprise risk management.
That shift explains why venture capital continues flowing toward healthcare infrastructure capable of managing longitudinal patient relationships rather than episodic transactions. Define Ventures clearly sees 9amHealth as part of that infrastructure layer.
What This Signals About Digital Health
The digital health market is quietly entering a post-hype phase. During the pandemic-era funding boom, investors rewarded growth narratives almost indiscriminately, and healthcare startups raised enormous rounds around virtual access, convenience, and engagement metrics. Public markets eventually started demanding operational discipline and measurable outcomes, forcing every “future of healthcare” pitch deck to answer uncomfortable questions about margins, retention, reimbursement, and clinical efficacy.
The companies surviving this reset increasingly share similar characteristics because they operate inside high-cost healthcare categories, produce measurable economic outcomes, integrate clinical workflows rather than simply overlay software, and align directly with employer and payer incentives. 9amHealth checks several of those boxes, although healthcare remains one of the most operationally brutal industries in technology.
Scaling chronic care requires clinical staffing, reimbursement management, regulatory compliance, patient retention, and relentless operational execution. Silicon Valley loves software margins, but healthcare regularly responds by handing founders a stack of prior authorization paperwork and asking whether they still feel optimistic. Investors continue backing companies attacking chronic disease because the underlying market pressure keeps intensifying and the economics remain too large to ignore.
The Bigger Industry Shift
The broader shift happening underneath healthcare is structural consolidation around continuous care models. Patients increasingly expect healthcare to function like modern consumer software: accessible, personalized, responsive, and integrated across devices, prescriptions, diagnostics, and providers. Employers want lower costs, health plans want fewer catastrophic claims, pharmaceutical manufacturers want adherence, and investors want scalable economics.
Everybody wants a cleaner operating system for chronic care, but that does not mean every virtual-care startup survives. The category is heading toward a brutal separation between companies with durable care-delivery infrastructure and companies built primarily around marketing arbitrage. 9amHealth’s Series B suggests investors believe the company belongs in the first category.
The next phase will depend less on storytelling and more on execution density because healthcare eventually audits everyone. Markets tolerate hype for a while, but chronic disease economics eventually force reality into the room.
Frequently Asked Questions
What is 9amHealth?
9amHealth is a San Diego-based virtual specialty care company focused on cardiometabolic conditions including diabetes, obesity, hypertension, and high cholesterol.
How much funding has 9amHealth raised?
9amHealth has raised roughly $51M in disclosed funding, including its recent $26M Series B round led by Define Ventures.
Who founded 9amHealth?
9amHealth was founded in 2021 by Frank Westermann, Anton Kittelberger, Paul Geevarghese, and Bernhard Schandl.
Who invested in the 9amHealth Series B round?
Define Ventures led the round, with participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures.
Why is cardiometabolic care attracting investors?
Cardiometabolic conditions such as obesity and diabetes drive significant employer healthcare and pharmacy spending, creating demand for scalable chronic-care infrastructure.
What makes 9amHealth different from other digital health startups?
9amHealth combines virtual specialty care, diagnostics, medication management, coaching, and continuous monitoring into a unified chronic-care platform designed for employers and health plans.